---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-096572"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:12:54.072542+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharma Board approves retention program with performance-based equity grants to CEO

## Summary
- CEO Sumit Aggarwal granted 75,000 performance RSUs and 25,000 performance stock options (exercise price $4.63).
- Awards vest upon earliest of: $35M market cap, $25M capital raise, or change in control.
- Future grants of 60,000 RSUs to CEO and 20,000 RSUs to Head of R&D Vijay Modur, subject to share availability.
- Additional 50,000 stock option for CEO under same condition, with exercise price not greater than $4.63.

## SEC filing metadata
- accession: 0001104659-23-096572
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923096572/0001104659-23-096572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923096572/tm2325066d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-096572
- JSON: https://secwatch.observer/filing/0001104659-23-096572.json
- Plain text: https://secwatch.observer/filing/0001104659-23-096572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.